CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1338-1348

  Yan, Yaping ^a,b   Ding, Xiaoli ^a,b   Li, Ke ^a   Ciric, Bogoljub ^a   Wu, Shuai ^a   Xu, Hui ^a   Gran, Bruno ^c   Rostami, Abdolmohamad ^a   Zhang, Guang Xian ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b SHAANXI NORMAL UNIVERSITY   (China)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; LENTIVIRUS VECTOR; PROTEIN ACT1; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACT1 GENE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTROCYTE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IMMUNIZATION; INFLAMMATORY INFILTRATE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; SIGNAL TRANSDUCTION; TH17 CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALIA;

EID: 84863463743     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.12     Document Type: Article

References (51)

1. Baxter, AG (2007). The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7: 904-912. (Pubitemid 350006239)
2. Hohlfeld, R (1997). Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 (Pt 5): 865-916.
3. Peterson, LK and Fujinami, RS (2007). Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 184: 37-44. (Pubitemid 46389415)
4. Krakowski, ML and Owens, T (2000). Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur J Immunol 30: 1002-1009. (Pubitemid 30216215)
5. Greenberg, BM and Calabresi, PA (2008). Future research directions in multiple sclerosis therapies. Semin Neurol 28: 121-127. (Pubitemid 351273089)
6. Segal, BM (2003). Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr Allergy Asthma Rep 3: 86-93. (Pubitemid 38899091)
7. Shevach, EM, Chang, JT and Segal, BM (1999). The critical role of IL-12 and the IL-12R beta 2 subunit in the generation of pathogenic autoreactive Th1 cells. Springer Semin Immunopathol 21: 249-262. (Pubitemid 30011438)
8. Lovett-Racke, AE, Yang, Y and Racke, MK (2011). Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 1812: 246-251.
9. Gran, B, Zhang, GX, Yu, S, Li, J, Chen, XH, Ventura, ES et al. (2002). IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 169: 7104-7110. (Pubitemid 36899299)
10. Zhang, GX, Gran, B, Yu, S, Li, J, Siglienti, I, Chen, X et al. (2003). Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol 170: 2153-2160. (Pubitemid 36197439)
11. Harrington, LE, Hatton, RD, Mangan, PR, Turner, H, Murphy, TL, Murphy, KM et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132. (Pubitemid 41541790)
12. Park, H, Li, Z, Yang, XO, Chang, SH, Nurieva, R, Wang, YH et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141. (Pubitemid 41541791)
13. Cua, DJ, Sherlock, J, Chen, Y, Murphy, CA, Joyce, B, Seymour, B et al. (2003). Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748. (Pubitemid 36227625)
14. El-Behi, M, Ciric, B, Dai, H, Yan, Y, Cullimore, M, Safavi, F et al. (2011). The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12: 568-575.
15. Aggarwal, S and Gurney, AL (2002). IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71: 1-8. (Pubitemid 34062767)
16. Chang, SH and Dong, C (2011). Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 23: 1069-1075.
17. Kolls, JK and Lindén, A (2004). Interleukin-17 family members and inflammation. Immunity 21: 467-476. (Pubitemid 39370503)
18. Komiyama, Y, Nakae, S, Matsuki, T, Nambu, A, Ishigame, H, Kakuta, S et al. (2006). IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 177: 566-573. (Pubitemid 43939170)
19. Matusevicius, D, Kivisäkk, P, He, B, Kostulas, N, Ozenci, V, Fredrikson, S et al. (1999). Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5: 101-104. (Pubitemid 29186827)
20. McFarland, HF and Martin, R (2007). Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8: 913-919. (Pubitemid 47300005)
21. Tzartos, JS, Friese, MA, Craner, MJ, Palace, J, Newcombe, J, Esiri, MM et al. (2008). Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172: 146-155. (Pubitemid 351186376)
22. Nair, A, Frederick, TJ and Miller, SD (2008). Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65: 2702-2720.
23. Dong, Y and Benveniste, EN (2001). Immune function of astrocytes. Glia 36: 180-190. (Pubitemid 33055906)
24. Calderon, TM, Eugenin, EA, Lopez, L, Kumar, SS, Hesselgesser, J, Raine, CS et al. (2006). A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 177: 27-39. (Pubitemid 44108231)
25. Oksenberg, JR, Seboun, E and Hauser, SL (1996). Genetics of demyelinating diseases. Brain Pathol 6: 289-302. (Pubitemid 26246384)
26. Kang, Z, Altuntas, CZ, Gulen, MF, Liu, C, Giltiay, N, Qin, H et al. (2010). Astrocyterestricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity 32: 414-425.
27. Farias, AS, de la Hoz, C, Castro, FR, Oliveira, EC, Ribeiro dos Reis, JR, Silva, JS et al. (2007). Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination. Neuroimmunomodulation 14: 32-38. (Pubitemid 47340633)
28. Chen, Y, Langrish, CL, McKenzie, B, Joyce-Shaikh, B, Stumhofer, JS, McClanahan, T et al. (2006). Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116: 1317-1326.
29. Zou, W and Restifo, NP (2010). T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10: 248-256.
30. Morrison, PJ, Ballantyne, SJ and Kullberg, MC (2011). Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 133: 397-408.
31. van de Veerdonk, FL, Gresnigt, MS, Kullberg, BJ, van der Meer, JW, Joosten, LA and Netea, MG (2009). Th17 responses and host defense against microorganisms: an overview. BMB Rep 42: 776-787.
32. Lee, Y, Messing, A, Su, M and Brenner, M (2008). GFAP promoter elements required for region-specific and astrocyte-specific expression. Glia 56: 481-493.
33. Bauer, M, Kinkl, N, Meixner, A, Kremmer, E, Riemenschneider, M, Förstl, H et al. (2009). Prevention of interferon-stimulated gene expression using microRNAdesigned hairpins. Gene Ther 16: 142-147.
34. Boden, D, Pusch, O, Silbermann, R, Lee, F, Tucker, L and Ramratnam, B (2004). Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 32: 1154-1158. (Pubitemid 38854717)
35. Laan, M, Cui, ZH, Hoshino, H, Lötvall, J, Sjöstrand, M, Gruenert, DC et al. (1999). Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 162: 2347-2352. (Pubitemid 29288861)
36. Franklin, RJ and Ffrench-Constant, C (2008). Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 9: 839-855.
37. Yang, J, Jiang, Z, Fitzgerald, DC, Ma, C, Yu, S, Li, H et al. (2009). Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis. J Clin Invest 119: 3678-3691.
38. Rasmussen, S, Imitola, J, Ayuso-Sacido, A, Wang, Y, Starossom, SC, Kivisäkk, P et al. (2011). Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol 69: 878-891.
39. Nakayama, T, Momoki-Soga, T and Inoue, N (2003). Astrocyte-derived factors instruct differentiation of embryonic stem cells into neurons. Neurosci Res 46: 241-249. (Pubitemid 36593287)
40. Das Sarma, J, Ciric, B, Marek, R, Sadhukhan, S, Caruso, ML, Shafagh, J et al. (2009). Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflammation 6: 14.
41. Mi, S, Hu, B, Hahm, K, Luo, Y, Kam Hui, ES, Yuan, Q et al. (2007). LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13: 1228-1233. (Pubitemid 47530642)
42. Croxford, JL, Feldmann, M, Chernajovsky, Y and Baker, D (2001). Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J Immunol 166: 4124-4130. (Pubitemid 32224944)
43. Fiandaca, MS and Bankiewicz, KS (2010). Gene therapy for Parkinson's disease: from non-human primates to humans. Curr Opin Mol Ther 12: 519-529.
44. Escors, D and Breckpot, K (2010). Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 58: 107-119.
45. Bank, A, Dorazio, R and Leboulch, P (2005). A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 1054: 308-316. (Pubitemid 43031038)
46. Di Cianni, S, Rossi, M, Casati, A, Cocco, C and Fanelli, G (2008). Spinal anesthesia: an evergreen technique. Acta Biomed 79: 9-17.
47. Winn, SR and Emerich, DF (2005). Managing chronic pain with encapsulated cell implants releasing catecholamines and endogenous opiods. Front Biosci 10: 367-378. (Pubitemid 40543039)
48. Jin, D, Liu, HX, Hirai, H, Torashima, T, Nagai, T, Lopatina, O et al. (2007). CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446: 41-45. (Pubitemid 46348037)
49. Yan, Y, Zhang, GX, Gran, B, Fallarino, F, Yu, S, Li, H et al. (2010). IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 185: 5953-5961.
50. Zhou, Y, Sonobe, Y, Akahori, T, Jin, S, Kawanokuchi, J, Noda, M et al. (2011). IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 186: 4415-4421.
51. Yang, J, Yan, Y, Ciric, B, Yu, S, Guan, Y, Xu, H et al. (2010). Evaluation of bone marrow-and brain-derived neural stem cells in therapy of central nervous system autoimmunity. Am J Pathol 177: 1989-2001.